Deals
Goldman Salvages Fees With Bausch After Failed Deals
This article is for subscribers only.
Sometimes deals that never happen are the best kind -- at least for Goldman Sachs Group Inc.
In recent months the New York-based investment bank failed to put together three potential mergers in the health-care industry. Yet Goldman Sachs managed to pull a takeover out of the wreckage --Valeant Pharmaceuticals International Inc.’s $8.7 billion acquisition of contact-lens maker Bausch & Lomb Holdings Inc., announced this week.